ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS
ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS
批准号:
7603699
负责人:
WILLIAM J MC CUNE
金额:
$0.9万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2007-09-16
关键词:
AdultAgeAntiphospholipid AntibodiesArterial InjuryArteriesBlood VesselsCalciumCardiovascular DiseasesCessation of lifeChildClinicalClinical DataComputer Retrieval of Information on Scientific Projects DatabaseCoronary arteryDevelopmentDilatation - actionDiseaseFunctional disorderFundingFutureGrantInjuryInstitutionLaboratoriesLupusMeasurementMeasuresMedialMediatingMichiganPathological DilatationPatientsPhysiologicalPrevalencePrevention strategyRecruitment ActivityResearchResearch PersonnelResourcesRiskScreening procedureSourceSpiral Computed TomographyStimulusSystemic Lupus ErythematosusTestingTherapeutic InterventionThickTimeUltrasonographyUnited States National Institutes of HealthVisitWomanbrachial arterycohortcoronary artery calcificationdisorder control
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
心血管疾病是儿童和成人狼疮(SLE)患病和死亡的主要原因。年轻女性狼疮患者的心血管疾病(CAD)患病率是年龄匹配的对照组的50倍。为了识别高危患者并研究预防策略,发现预测系统性红斑狼疮患者冠心病发展的早期变化是重要的。我们将评估三种血管损伤的无创性测试,包括血流介导的臂动脉扩张(FMD),超声测量颈动脉内中膜厚度(CIMT),以及螺旋CT(HCT)测量冠状动脉钙。FMD测量动脉对生理刺激的反应能力。FMD在成人狼疮患者中是异常的,但在儿童狼疮患者中尚未被描述。疾病活动性或抗磷脂抗体(APA)是否会加重SLE患者的FMD尚不清楚。我们将从密歇根狼疮队列中招募患者,他们以系统化的方式收集了大量的临床数据。在基线访问中,我们将描述FMD的特征及其与临床疾病特征、CIMT、Hct、APA和预测动脉损伤的实验室测试的关系。患有狼疮的成人和儿童将与“健康”的对照组进行比较。我们将检验这些假设:(1)儿童和成人狼疮患者在亚临床心血管疾病的这些测量中比对照组有更多的异常,(2)APA和SLE活动增加预示着更糟糕的FMD。
然后我们将纵向跟踪狼疮患者的FMD,CIMT和Hct的测量。我们将检验这一假设,即功能异常,FMD降低,预测CIMT测量的CAD解剖变化的进展和Hct测量的冠状动脉钙化。如果异常的FMD识别出未来会患上冠心病的患者,那么它可能会作为候选治疗干预措施的筛查测试。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Cardiovascular disease is a major cause of illness and death in children and adults with lupus (SLE). The prevalence of cardiovascular disease (CAD) in young women with lupus is 50 times that of age-matched controls. In order to identify patients at risk and to study preventive strategies, it is important to detect early changes that predict development of CAD in SLE. We will evaluate three noninvasive tests for vascular injury, including flow-mediated brachial artery dilatation (FMD), carotid intimal-medial thickness (CIMT) measurement by ultrasound, and helical computed tomography (HCT) measurement of coronary artery calcium. FMD measures the ability of arteries to respond to physiologic stimuli. FMD is abnormal in adult lupus patients but is not yet described in children with lupus. It is not known whether disease activity or antiphospholipid antibodies (APA) worsen FMD in SLE. We will recruit patients from the Michigan Lupus Cohort, who have extensive clinical data collected in a systematized fashion. At the baseline visit we will characterize FMD and its relation to clinical disease features, CIMT, HCT, APA, and laboratory tests that predict arterial injury. Adults and children with lupus will be compared with "healthy" controls. We will test these hypotheses: (1) Children and adults with lupus have more abnormalities in these measurements of subclinical cardiovascular disease than controls, and (2) APA and increased SLE activity predict worse FMD.
We will then longitudinally follow the lupus patients with measurements of FMD, CIMT and HCT. We will test the hypothesis that a functional abnormality, decreased FMD, predicts progression of anatomical changes of CAD, as measured by CIMT and calcification of coronary arteries by HCT. If abnormal FMD identifies patients who will develop CAD in the future, then it may be useful as a screening test for candidate therapeutic interventions.'
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease
-
批准号:8469875
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:WILLIAM J MC CUNE
-
依托单位:
EFFICACY & SAFETY OF RITUXIMAB FOR MOD TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
-
批准号:7603826
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2007
-
负责人:WILLIAM J MC CUNE
-
依托单位:
ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS
-
批准号:7376497
-
项目类别:
-
资助金额:$3.78万
-
财政年份:2006
-
负责人:WILLIAM J MC CUNE
-
依托单位:
DOES DHEA IMPROVE ENDOTHELIAL DYSFUNCTION IN SLE?
-
批准号:7376530
-
项目类别:
-
资助金额:$1.43万
-
财政年份:2006
-
负责人:WILLIAM J MC CUNE
-
依托单位:
DOES DHEA IMPROVE ENDOTHELIAL DYSFUNCTION IN SLE?
-
批准号:7199849
-
项目类别:
-
资助金额:$1.44万
-
财政年份:2005
-
负责人:WILLIAM J MC CUNE
-
依托单位:
ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS
-
批准号:7199807
-
项目类别:
-
资助金额:$2.98万
-
财政年份:2005
-
负责人:WILLIAM J MC CUNE
-
依托单位:
TREATMENT WITH ETANERCEPT FOR WEGENER'S GRANULOMATOSIS
-
批准号:7199799
-
项目类别:
-
资助金额:$0.26万
-
财政年份:2005
-
负责人:WILLIAM J MC CUNE
-
依托单位:
Does DHEA Improve Endothelial Dysfunction in SLE?
-
批准号:7039823
-
项目类别:
-
资助金额:$0.61万
-
财政年份:2004
-
负责人:WILLIAM J MC CUNE
-
依托单位:
Endothelial Dysfunction in Children & Adults w/ Systemic Lupus Erythematosus
-
批准号:7039768
-
项目类别:
-
资助金额:$3.81万
-
财政年份:2004
-
负责人:WILLIAM J MC CUNE
-
依托单位:
Mycophenolate Mofetil vs. Placebo in Pts w/ Systemic Lupus Erythematosus
-
批准号:7039760
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2004
-
负责人:WILLIAM J MC CUNE
-
依托单位:
Treatment with Etanercept for Wegener's Granulomatosis
-
批准号:7039744
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2004
-
负责人:WILLIAM J MC CUNE
-
依托单位:
TREATMENT OF SEVERE SYSTEMIC LUPUS WITH MONTHLY INTRAVENOUS CYCLOPHOSPHAMIDE
-
批准号:6244515
-
项目类别:
-
资助金额:$2.22万
-
财政年份:1997
-
负责人:WILLIAM J MC CUNE
-
依托单位:
CHIMERIC ANTI-TNF MONOCLONAL ANTIBODY (CA2) IN ACTIVE RHEUMATOID ARTHRITIS
-
批准号:6244604
-
项目类别:
-
资助金额:$2.22万
-
财政年份:1997
-
负责人:WILLIAM J MC CUNE
-
依托单位:
CHIMERIC ANTI-TNF MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS
-
批准号:6244612
-
项目类别:
-
资助金额:$2.22万
-
财政年份:1997
-
负责人:WILLIAM J MC CUNE
-
依托单位:
TREATMENT OF SEVERE SYSTEMIC LUPUS WITH MONTHLY INTRAVENOUS CYCLOPHOSPHAMIDE
-
批准号:6274575
-
项目类别:
-
资助金额:$2.15万
-
财政年份:1997
-
负责人:WILLIAM J MC CUNE
-
依托单位:
TREATMENT OF SEVERE SYSTEMIC LUPUS
-
批准号:5216117
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM J MC CUNE
-
依托单位:--
CHIMERIC ANTI TNF MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS
-
批准号:5217651
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:WILLIAM J MC CUNE
-
依托单位:--
TREATMENT OF SEVERE SYSTEMIC LUPUS WITH MONTHLY INTRAVENOUS CYCLOPHOSPHAMIDE
-
批准号:6113341
-
项目类别:
-
资助金额:$2.14万
-
财政年份:--
-
负责人:WILLIAM J MC CUNE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: